{
  "item1": "anitocabtagene autoleucel, CAR T-cell therapy, being evaluated patients relapsed and/or refractory multiple myeloma who received one three prior lines therapy. Sacituzumab govitecan-hziy breast cancer, sacituzumab govitecan-hziy being evaluated (i) first-line treatment PD-L1 negative metastatic TNBC (ii) HR+/HER2- chemo-naive metastatic breast cancer. collaboration Merck, also being evaluated combination Merck’s pembrolizumab (i) first-line treatment PD-L1 positive metastatic TNBC (ii) adjuvant treatment early TNBC. lung thoracic cancer, sacituzumab govitecan-hziy being evaluated combination Merck’s pembrolizumab first-line treatment PD-L1 positive non-small cell lung cancer (“NSCLC”).",
  "item7": "Includes Atripla, Complera/Eviplera, Emtriva, Stribild, Sunlenca, Truvada Tybost. Includes Epclusa authorized generic version Epclusa sold Gilead’s separate subsidiary, Asegua Therapeutics LLC (“Asegua”). Includes ledipasvir/sofosbuvir (Harvoni authorized generic version Harvoni sold Asegua), Hepcludex, Hepsera, Livdelzi, Sovaldi, Viread Vosevi. Includes Cayston, Jyseleca, Letairis, Ranexa Zydelig.",
  "item2": "Item 2. MANAGEMENT’S DISCUSSION ANALYSIS FINANCIAL CONDITION RESULTS OPERATIONS Gilead Sciences, Inc. (including its consolidated subsidiaries, referred “Gilead,” “company,” “we,” “our” “us”) biopharmaceutical company pursued achieved breakthroughs medicine more than three decades, goal creating healthier world all people. committed advancing innovative medicines prevent treat life-threatening diseases, including HIV, viral hepatitis, coronavirus disease 2019 (“COVID-19”), cancer inflammation."
}